CTOs on the Move

SimBioSys Inc

www.simbiosys.ca

 
SimBioSys Inc is a Etobicoke, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.simbiosys.ca
  • 135 Queens Plate Dr
    Etobicoke, ON CAN M9W 6V1
  • Phone: 406.741.5084

Executives

Name Title Contact Details

Similar Companies

Seattle Biomedical Research Institute

Seattle Biomedical Research Institute is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immunomedics

Immunomedics is a leader in next-generation antibody-drug conjugate (ADC) technology, committed to help transform the lives of people with hard-to-treat cancers.

Solid Biosciences

Solid Biosciences (Solid) is a life science company singularly focused on solving Duchenne muscular dystrophy (Duchenne). We aim to be the center of excellence across the entire disease spectrum, serving as a catalyst to bring together those with the expertise in science, technology, disease management and care. Disease-focused and founded by a family directly impacted, our mandate is simple yet comprehensive - attack the roots of the disease and improve daily life for patients. Solid is headquartered in Cambridge, MA, USA.

Vaxin

Vaxin is a clinical stage immunotherapeutic biotechnology company located in Montgomery County, MD with additional operating sites in London, UK and Strasbourg, France. By leveraging the complementary attributes of its two innovative vaccine delivery platforms, RespirVec™ and Densigen™, Vaxin is able to rationally design and rapidly develop immunotherapeutic products tailored to address the a wide range of disease indications including acute respiratory infections, chronic viral infections and cancer with fundamental advantages over competing products. Our mission at Vaxin is to protect and preserve public health by providing effective and safe vaccines that prevent disease outbreak.

Eidos Therapeutics

Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis.